• Vaccine Name: H. influenzae Omp26 protein vaccine
• Target Pathogen: Haemophilus influenzae
• Target Disease: Meningitis
• Vaccine Ontology ID: VO_0011562
• Type: Subunit vaccine
• Status: Research
• Antigen: H. influenzae outer membrane protein 26
• skp gene engineering:
  • Type: Recombinant protein preparation
  • Description: A crude outer membrane preparation was obtained from bacteria grown overnight on agar plates, and OMP26 was purified by preparative polyacrylamide gel electrophoresis (PAGE) as previously described. Preparative SDS-PAGE to purify OMP26 was performed with a Bio-Rad model 491 Prep Cell, using a 60-ml 14% T-1.42% C acrylamide-BIS (N,N′-methylenebisacrylamide) separating gel with a 10-ml 4% T-0.36% C acrylamide-BIS stacking gel polymerized in a 37-mm (internal diameter) column. Fractions were concentrated by lyophilization and analyzed for protein content by analytical SDS-PAGE. OMP26 isolated under these conditions contained SDS, which was subsequently removed. Fractions containing OMP26 were pooled and dialyzed prior to determination of protein concentration. The presence of lipooligosaccharide (LOS) was assessed by both silver staining of SDS-PAGE minigels and assaying with the E-TOXATE Limulus lysate test (Sigma, Castle Hill, New South Wales, Australia) (Kyd and Cripps, 1998).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000142
• Immunization Route: Subserosal injection

Rat Response

• Host Strain: DA
• Vaccination Protocol: The immunization protein was prepared by emulsifying 200 or 800 μg of protein per ml in a 1:1 ratio of incomplete Freund’s adjuvant (IFA; Difco Laboratories, Detroit, Mich.), and phosphate-buffered saline (PBS), and a total inoculum of 10 or 40 μg of protein, respectively, was administered to each animal via subserosal injection of intestinal Peyer’s patches (IPP) (Kyd and Cripps, 1998).
• Challenge Protocol: Pulmonary challenge with live bacteria was performed on day 21 post-IPP immunization. The animals were sedated with halothane, and a bolus inoculum of 5 × 10^8 CFU of live H. influenzae in 50 μl of PBS was introduced into the lungs via an i.t. cannula and dispersed with two 5-ml volumes of air (Kyd and Cripps, 1998).
• Efficacy: OMP26 was used to immunize rats via intestinal Peyer's patches, followed by an intratracheal boost. Immunization was found to significantly enhance bacterial clearance following pulmonary challenge with both the homologous NTHI strain and a different NTHI strain (Kyd and Cripps, 1998).
• Host IgA response
  • Description: High OMP26-specific antibody titers for IgG, IgA, and IgM were found in the serum. The results were significantly higher than non-immunized mice for groups receiving 10 micrograms and 40 micrograms of the vaccine (Kyd and Cripps, 1998).
  • Detailed Gene Information: Click Here.
• Host IgG (partial) response
  • Description: High OMP26-specific antibody titers for IgG, IgA, and IgM were found in the serum. The results were significantly higher than non-immunized mice for groups receiving 10 micrograms and 40 micrograms of the vaccine (Kyd and Cripps, 1998).
  • Detailed Gene Information: Click Here.
• Host IgM response
  • Description: High OMP26-specific antibody titers for IgG, IgA, and IgM were found in the serum. The results were significantly higher than non-immunized mice for groups receiving 10 micrograms and 40 micrograms of the vaccine (Kyd and Cripps, 1998).
  • Detailed Gene Information: Click Here.